Detalhe da pesquisa
1.
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
J Nanobiotechnology
; 21(1): 478, 2023 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38087362
2.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler
; 28(3): 429-440, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34240656
3.
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment.
Muscle Nerve
; 64(5): 532-537, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378224
4.
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
J Nanobiotechnology
; 22(1): 16, 2024 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167088
5.
On being a neurologist in industry.
Ann Neurol
; 73(3): 319-26, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23423974
6.
EDSS variability before randomization may limit treatment discovery in primary progressive MS.
Mult Scler
; 19(6): 775-81, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23027880
7.
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
EClinicalMedicine
; 60: 102036, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396808
8.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Lancet
; 378(9805): 1779-87, 2011 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22047971
9.
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.
BMJ Open
; 11(1): e041479, 2021 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33431491
10.
Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.
J Neurol Sci
; 426: 117463, 2021 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971376
11.
The role of optical coherence tomography in multiple sclerosis: expert panel consensus.
J Neurol Sci
; 263(1-2): 3-14, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17673257
12.
Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.
Mult Scler Relat Disord
; 15: 18-23, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28641767
13.
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Mult Scler Relat Disord
; 9: 95-100, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27645352
14.
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Clin Ther
; 25(1): 81-104, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12637113
15.
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Clin Ther
; 25(10): 2597-608, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14667960